Papers

2024

Li H, Zhang L, Li J, Wu Q, Qian L, He J, Ni Y, Kovatcheva-Datchary P, Yuan R, Liu S, Shen L, Zhang M, Sheng B, Li P, Kang K, Wu L, Fang Q, Long X, Liu X, Wang X, Li Y, Ye Y, Ye J, Bao Y, Zhao Y, Xu G, Panagiotou G*, Xu A*, and Jia W* (2024). Resistant starch intake facilitates weight loss in humans by reshaping the gut microbiota. Nature Metabolism. 2024 Feb 26. DOI

Garcia-Morena D*, Fernandez-Cantos MV*, Lopez Escalera S*, Lok J*, Iannone V*, Cancellieri P, Maathuis W, Panagiotou G*, Aranzamendi C, El Aidy S, Kolehmainen M, El‑Nezami H*, Wellejus A*, Kuipers OP* (2024). In-vitro influence of specific Bacteroidales strains on gut and liver health related to Metabolic dysfunction-associated fatty liver disease . Probiotics Antimicrob Proteins. 2024 Feb 6. DOI

Sands C, Hedin KA*, Vazquez-Uribe R, Sommer MOA* (2024). Saccharomyces boulardii promoters for control of gene expression in vivo. Microb Cell Fact. 2024 Jan 7;23(1):16. DOI

2023

Guo L, Wambui J, Wang C, Muchaamba F, Fernandez-Cantos MV*, Broos J, Tasara T, Kuipers OP*, Stephan R (2023). Cesin, a short natural variant of nisin, displays potent antimicrobial activity against major pathogens despite lacking two C-terminal macrocycles. Microbiol Spectr. 2023 Sept 27;11(5):e0531922 DOI

Fernandez-Cantos MV*, Garcia-Morena D*, Yi Y, Liang L, Gómez-Vázquez E, Kuipers OP* (2023). Bioinformatic mining for RiPP biosynthetic gene clusters in Bacteroidales reveals possible new subfamily architectures and novel natural products. Front Microbiol. 2023 Jul 4:14:1219272. DOI

Csader S*, Ismaiah MJ, Kuningas T, Heinäniemi M, Suhonen J, Männistö V, Pentikäinen H, Savonen K, Tauriainen MM, Galano JM, Lee JCY, Rintamäki R, Karisola P, El-Nezami H*, Schwab U* (2023). Twelve Weeks of High-Intensity Interval Training Alters Adipose Tissue Gene Expression but Not Oxylipin Levels in People with Non-Alcoholic Fatty Liver Disease. Int J Mol Sci May 9;24(10):8509. DOI

Hedin KA*, Zhang H, Kruse V, Rees VE, Bäckhed F, Greiner TU, Vazquez-Uribe R, Sommer MOA* (2023). Cold Exposure and Oral Delivery of GLP-1R Agonists by an Engineered Probiotic Yeast Strain Have Antiobesity Effects in Mice. ACS Synth. Biol. Nov 17;12(11):3433-3443. DOI

Iannone V*, Babu AF*, Lok J**, Gómez-Gallego C, D'Auria G, Vazquez-Uribe R, Vaaben TH, Bongers M, Mikkonen S, Vaittinen M, Tikkanen I, Kettunen M, Klåvus A, Sehgal R, Kaminska D, Pihlajamaki J, Hanhineva K*, El-Nezami H*, Sommer MOA*, Kolehmainen M* (2023). Changes in liver metabolic pathways demonstrate efficacy of the combined dietary and microbial therapeutic intervention in MASLD mouse model. Mol Metab. Oct 13:101823. DOI

Ni Y, Qian L, Leal Siliceo S*, Long X, Nychas E*, Liu Y, Ismaiah MJ,6,7 Leung H*, Zhang L, Gao Q, Wu Q, Zhang Y, Jia X, Liu S, Yuan R, Zhou L, Wang X, Li Q, Zhao Y, El-Nezami H*, Xu A*, Xu G, Li H, Panagiotou G*, Jia W* (2023). Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations. Cell Metabolism. Sept 05;35, 1530-1547. DOI

Csader S*, Chen X, Leung H*, Männistö V, Pentikäinen H, Tauriainen M-M,Savonen K, El-Nezami H*, Schwab U*, Panagiotou G* (2023). Gut ecological networks reveal associations between bacteria, exercise, and clinical profile in non-alcoholic fatty liver disease patients. mSystems. August 22;e0022423. DOI

Chen J, Leal Siliceo S*, Ni Y, Nielsen HB*, Xu A, Panagiotou G* (2023). Identification of robust and generalizable biomarkers for microbiome-based stratification in lifestyle interventions. Microbiome. August 8;11(1):178. DOI

Leung H*, Xiong L, Ni Y, Busch A, Bauer M, Press AT, Panagiotou G* (2023). Impaired flux of bile acids from the liver to the gut reveals microbiome-immune interactions associated with liver damage. npj Biofilms and Microbiomes. Jun 7;9(1):35. DOI

Lopez-Escalera S*, Lund ML, Hermes GDA, Choi BSY, Sakamoto K, Wellejus A* (2023). In Vitro Screening for Probiotic Properties of Lactobacillus and Bifidobacterium Strains in Assays Relevant for Non-Alcoholic Fatty Liver Disease Prevention. Nutrients. May 18;15,2361. DOI

Iannone V*, Lok J*, Babu AF*, Gómez-Gallego C, Willman RM, Koistinen VM, Klåvus A, Kettunen MI, Kårlund A, Schwab U*, Hanhineva K*, Kolehmainen M, El Nezami H* (2023). Associations of altered hepatic gene expression in American lifestyle-induced obesity syndrome diet-fed mice with metabolic changes during NAFLD development and progression. J Nutr Biochem. Mar 1;109307. DOI

Hedin KA*, Kruse V, Vazquez-Uribe R, Sommer MOA* (2023). Biocontainment strategies for in vivo applications of Saccharomyces boulardii.Front Bioen Biotechnol. 11: 1136095. DOI

Houttu V*, Grefhorst A, Cohn DM, Levels JHM, Roeters van Lennep J, Stroes ESG, Groen AK, Tromp TR (2023). Severe Dyslipidemia Mimicking Familial Hypercholesterolemia Induced by High-Fat, Low-Carbohydrate Diets: A Critical Review. Nutrients. Feb 15; 15(4):962. DOI

2022

Houttu V*, Bouts J, Vali Y, Daams J, Grefhorst A, Nieuwdorp M*, Holleboom AG. (2022). Does aerobic exercise reduce NASH and liver fibrosis in patients with non-alcoholic fatty liver disease? A systematic literature review and meta-analysis. Front. Endocrinol. DOI

Zarei I, Koistinen V.M, Kokla M, Klåvus A, Babu A.F*, Lehtonen M, Auriola S, and Hanhineva K*. (2022). Tissue-wide metabolomics reveals wide impact of gut microbiota on mice metabolite composition. Sci Rep. 12:15018. DOI

Jia W*, Panagiotou G*. (2022). Recent advances in diabetes and microbiota. Science Bulletin. 67(17):1720-1723. DOI

Garcia-Morena D*, Lok J*, Lopez-Escalera S*, Fernandez-Cantos M.V*, Babu A*, Aranzamendi C, El Aidy S, Hanhineva K*, El-Nezamy H*, Kuipers O.P* and Wellejus A*. (2022). Can microbiota modulation prevent the development of fatty liver disease? Project Repository Journal. 14:pp.66-69. DOI

Lopez-Escalera S*, Wellejus A*. (2022). Evaluation of Caco-2 and human intestinal epithelial cells as in vitro models of colonic and small intestinal integrity. Biochemistry and Biophysics Reports. 31:101314. DOI

Leung H*, Long X, Ni Y, Qian L, Nychas E*, Leal Siliceo S*, Pohl D*, Hanhineva K*, Liu Y, Xu A*, Nielsen HB*, Belda E, Clément K, Loomba R, Li H, Jia W*, Panagiotou G*. (2022). Risk assessment with gut microbiome and metabolite markers in NAFLD development. Sci Transl Med. 14(648):eabk0855. DOI

Hedin KA*, Rees VE, Zhang H, Vibeke Kruse, Vazquez-Uribe R, Sommer M*. (2022). Effects of broad-spectrum antibiotics on the colonisation of probiotic yeast Saccharomyces boulardii in the murine gastrointestinal tract. Sci Rep.12:8862. DOI

Babu AF*, Csader S*, Männistö V, Tauriainen MM, Pentikäinen H, Savonen K, Klåvus A, Koistinen V, Hanhineva K*, Schwab U* (2022). Effects of exercise on NAFLD using non-targeted metabolomics in adipose tissue, plasma, urine, and stool. Sci Rep.12(1):6485. DOI

Babu AF*, Koistinen VM, Turunen S, Solano-Aguilar G, Urban JF Jr., Zarei I, Hanhineva K* (2022). Identification and Distribution of Sterols, Bile Acids, and Acylcarnitines by LC-MS/MS in Humans, Mice, and Pigs-A Qualitative Analysis. Metabolites. 12(1):49. DOI

2021

Armetta J*, Schantz-Klausen M, Shepelin D, Vazquez-Uribe R, Bahl M.I, Laursen M.F, Licht T.R, Sommer M.O.A*. (2021). Escherichia coli Promoters with Consistent Expression throughout the Murine Gut. ACS Synth. Biol. 10,12:3359–3368. DOI

Babu AF*, Csader S*, Lok J*, Gómez-Gallego C, Hanhineva K*, El-Nezami H*, Schwab U* (2021). Positive Effects of Exercise Intervention without Weight Loss and Dietary Changes in NAFLD-Related Clinical Parameters: A Systematic Review and Meta-Analysis. Nutrients 13(9):3135. DOI

Fernandez-Cantos MV*, Garcia-Morena D*, Iannone V*, El-Nezami H*, Kolehmainen M*, Kuipers OP* (2021). Role of microbiota and related metabolites in gastrointestinal tract barrier function in NAFLD. Tissue Barriers 19:1879719. DOI

Houttu V*, Boulund U*, Nicolaou M, Holleboom AG, Grefhorst A, Galenkamp H, van den Born B-J, Zwinderman K, Nieuwdorp M* (2021). Physical Activity and Dietary Composition Relate to Differences in Gut Microbial Patterns in a Multi-Ethnic Cohort—The HELIUS Study. Metabolites. 11(12):858. DOI

Houttu V*, Csader S*, Nieuwdorp M*, Holleboom AG, Schwab U* (2021). Dietary Interventions in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Frontiers in Nutrition 8:437. DOI

Zhang J, Ni Y, Qian L, Fang Q, Zheng T, Zhang, M, Gao Q, Zhang Y, Ni, J, Bao Y, Kovatcheva-Datchary P, Xu A, Li H, Panagiotou G*, Jia W (2021). Decreased abundance of Akkermansia muciniphila leads to the impairment of insulin secretion and glucose homeostasis in lean type 2 diabetes. Advanced Science 4:e2100536. DOI

2020

Houttu V*, Boulund U*, Grefhorst A, Soeters MR, Pinto-Sietsma S-J, Nieuwdorp M* and Holleboom AG (2020). The role of the gut microbiome and exercise in non-alcoholic fatty liver disease. Therapeutic Advances in Gastroenterology 13: 1-21 DOI

2019

Zheng T, Li J, Ni Y, Kang K, Misiakou M-A, Imamovic L, Chow BKC, Rode AA, Bytzer P, Sommer M* and Panagiotou G*(2019). Mining, analyzing, and integrating viral signals from metagenomic data. Microbiome 7: 42 DOI

Liu Y, Wang Y, Ni Y, Cheung CKY, Lam KSL, Wang Y, Xia Z, Ye D, Guo J, Tse MA, Panagiotou G* and Xu A (2019). Gut microbiome fermentation determines the efficacy of exercise for diabetes prevention. Cell Metab 31(1): 77-91 DOI

*BestTreat affiliated